|
Cefaclor
Cefaclor (Ceclor)
Cefaclor
(
SEF-ah-klor)
Pregnancy Category: B
Apo-Cefaclor
Ceclor
Ceclor CD
PMS-Cefaclor
(Rx)
Classification:
Cephalosporin, second-generation
See Also:
See also
Anti-Infectives
[ and
Cephalosporins
][.
]
Action/Kinetics:
Peak serum levels: 5-15 mcg/mL after 1 hr.
t
1/2: PO, 36-54 min. Well absorbed from GI tract. From 60% to 85% excreted in urine within 8 hr.
Uses:
(1) Otitis media due to
Streptococcus pneumoniae, Hemophilus influenzae, Streptococcus pyogenes, and staphylococci. (2) Upper respiratory tract infections (including pharyngitis and tonsillitis) caused by
S. pyogenes. (3) Lower respiratory tract infections (including pneumonia) due to
S. pneumoniae, H. influenzae and
S. pyogenes. (4) Skin and skin structure infections due to
Staphylococcus aureus and
S. pyogenes. (5) UTIs (including pyelonephritis and cystitis) caused by
Escherichia coli, Proteus mirabilis, Klebsiella and coagulase-negative staphylococci.
Extended-
release tablets: (1) Acute bacterial exacerbations of chronic bronchitis due to non-ß-lactamase-producing strains of
H. influenzae, Moraxella catarrhalis (including ß
-lactamase-producing strains)
, or
S. pneumoniae. (2) Secondary bacterial infections of acute bronchitis due to
H. influenzae (non-ß-lactamase-producing strains only),
M. catarrhalis (including ß
-lactamase-producing strains), or
S. pneumoniae. (3) Pharyngitis or tonsillitis due to
S. pyogenes. (4) Uncomplicated skin and skin structure infections due to
S.
aureus (methicillin-susceptible).
Investigational: Acute uncomplicated UTIs in select populations using a single dose of 2 g.
Special Concerns:
Safety for use in infants less than 1 month of age has not been established.
Additional Side Effects:
Cholestatic jaundice, lymphocytosis.
How Supplied:
Capsule: 250 mg, 500 mg;
Powder for Reconstitution: 125 mg/5 mL, 187 mg/5 mL, 250 mg/5 mL, 375 mg/5 mL
; Tablet, Extended Release: 375 mg, 500 mg
Dosage
?Capsules, Oral Suspension
All uses.
Adults: 250 mg q 8 hr. Dose may be doubled in more severe infections or those caused by less susceptible organisms. Total daily dose should not exceed 4 g.
Children: 20 mg/kg/day in divided doses q 8 hr. Dose may be doubled in more serious infections, otitis media, or for infections caused by less susceptible organisms. For otitis media and pharyngitis, the total daily dose may be divided and given q 12 hr. Total daily dose should not exceed 2 g.
?Tablets, Extended Release
Acute bacterial exacerbations, chronic bronchitis, secondary bacterial infections of acute bronchitis.
500 mg q 12 hr for 7 days.
Pharyngitis, tonsillits.
375 mg q 12 hr for 10 days.
Uncomplicated skin and skin structure infections.
375 mg q 12 hr for 7-10 days. |
